Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. ABO blood types and sepsis mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Identification of two different coagulation phenotypes in people living with HIV with undetectable viral replication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Bleeding is a common adverse event following ibrutinib monotherapy. However, it remains unclear how hemostasis is affected by venetoclax in combination with ibrutinib. Here we investigated hemostasis in patients with chronic lymphocytic leukemia (CLL) at baseline, during ibrutinib monotherapy, and during venetoclax and ibrutinib combination therapy or venetoclax monotherapy. Primary hemostasis, assessed by Multiplate using adenosine diphosphate (ADP), arachidonic acid (AA), and thrombin receptor agonist peptide (TRAP-6), was impaired in all CLL patients at baseline, remained unchanged upon ibrutinib monotherapy, and improved significantly following venetoclax added to ibrutinib or as monotherapy. Secondary hemostasis assessed by thromboelastography (TEG) was normal and unchanged throughout treatment. The frequency of clinical bleeding events was the highest during ibrutinib monotherapy, in line with the demonstrated improved primary hemostasis upon addition of venetoclax, thus pointing toward a treatment option for CLL patients with increased bleeding risk.

OriginalsprogEngelsk
TidsskriftLeukemia and Lymphoma
Vol/bind61
Udgave nummer14
Sider (fra-til)3422-3431
Antal sider10
ISSN1042-8194
DOI
StatusUdgivet - dec. 2020

ID: 61698803